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Summary 
This study explores the usage of T cell antigen receptor (TCR) ~ chain elements in Lewis rats 
with experimentally induced allergic encephalomyelitis (EAE).  TCRs from 15 different T cell 
clones and hybridomas derived from animals immunized with myelin basic protein (MBP),  and 
all having specificity for the 21-mer encephalitogenic fragment MBP 68-88, utilized V~8.2. In 
addition, there was a marked conservation of the first two amino acid residues of the junctional 
complementarity determining region 3 (CDR3) associated with the V~8.2 receptors.  12 of 15 
contained an aspartic acid followed by serine regardless of the associated JB element. At the nudeo- 
tide level, this conservation of AspSer residues was accomplished with few or no nongermline- 
encoded nucleotide (N) additions. A similar pattern of AspSer usage and N  region nucleotide 
additions was observed in a number of V~8.2 isolates derived from MBP-immunized lymph 
nodes. In contrast, VB8.2 polymerase chain reaction amplified isolates from Lewis T cells activated 
with concanavalin A or from lymph nodes of complete Freund's adjuvant-immunized animals 
showed no AspSer utilization (0/31) in the CDR3, and four to nine N region nudeotide additions. 
We conclude from this finding that AspSer residues in the CDR3, limited N region nucleotide 
additions, along with V~8.2 sequences, contribute to TCR specificity for MBP 68-88.  This 
raises the possibility that encephalitogenic, disease-causing T cells either represent a population 
that derives from late fetal life or alternatively,  that they are rare cells with this particular TCR 
phenotype contributed to the T  cell pool throughout adulthood and are selected by antigen. 
In either case, the CDR3 AspSer sequences as well as V~8.2 sequences are candidates  for the 
receptor target structures recognized by regulator T cells in recovery from and resistance to active 
EAE. In this respect,  a preliminary analysis of TCR utilization in three T  cell clones specific 
for MBP 68-88 isolated from animals recovered from active EAE indicates that while all three 
use V~8.2, only one contains AspSer in the CDR3. 
N 
'early all T cell immune responses involve the recogni- 
tion by ot/3 heterodimeric TCR of antigen that has 
been processed and represented on the surface of APC as pep- 
tides bound to MHC molecules (1). TCR ot and 3  chains 
are each derived from multiple germline-encoded elements 
which undergo somatic recombination during T cell devel- 
opment. In the mouse, the repertoire of ot chain germline 
genes is thought to number approximately 100 different vari- 
able (Vot) segments and also 100 different joining (Jot) ele- 
ments. TCK/~ chains are derived from a repertoire of gene 
segments which has been estimated to consist of 25 different 
VB elements, 12 JB genes, and two diversity (D/~) elements. 
Random joining of these various  intra ot and ~  chain ele- 
ments plus combinatory associations  of different ot and B chains 
permit a considerable degree of TCR diversity. In addition, 
during the somatic process of V/J recombination (WD/J for 
/~ chains), further diversity is created in the  junctional regions 
through the addition of nongermline encoded nucleotides 
(N region). Given the number of different germline elements, 
the number of possible junctional region sequences, and the 
combinatory associations of the two chains, it has been esti- 
mated that  the potential TCR repertoire is  of the order 
1015-1022 specificities (2, 3). 
Theoretical modeling of the interaction between TCR. mol- 
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tain regions encoded within Vo~ and VB, corresponding to 
the CDR1 and CDR2 of Ig, interact with ol helices of the 
MHC molecule, and recognition of the MHC-associated pep- 
tide occurs  primarily via the (N)JoL and (N)Dfl(N)Jfl ele- 
ments comprising the CDR3 of the two chains (2,  4). 
Despite the very large number of possible TCR specificities, 
a number of studies have shown that the major portion of 
the T cell response to a number of different protein antigens 
is directed to a few immunodominant epitopes within the 
protein molecule. In addition, TCR utilization in these re- 
sponses, even to a single immunodominant epitope, is often 
quite limited (5-10).  An example of such a pauciclonal re- 
sponse, dominated by a single or a few TCR ol/fl chain com- 
binations, was first demonstrated to be the case for pigeon 
cytochrome c in H-2 '  mice (5). 
Another example of limited TCR utilization occurs in the 
immune response of rats immunized with guinea pig myelin 
basic  protein  (MBP) 1 to  induce experimental allergic  en- 
cephalomyelitis (EAE), a paralytic, T  cell-mediated demy- 
elinating autoimmune disease that is widely studied as an 
animal model for multiple sclerosis in humans (11). Here, 
the T cell response  of Lewis rats is directed primarily to an 
immunodominant epitope contained within the encephalito- 
genic amino acid 68-88 fragment of the MBP molecule (MBP 
68-88). This T cell response is also highly restricted, domi- 
nated by T  cells that use Vfl8 almost exclusively and Vot2 
frequently (12). 
This finding of conserved Vc~ and Vfl utilization in EAE 
raises the possibility that CDR3 junctional regions might 
also be utilized in a limited way since these are believed to 
be involved in recognition of the peptide in the MHC groove. 
Here we report TCR fl chain sequences of numerous T cell 
clones and hybridomas reactive to MBP 68-88. All utilized 
the Vf18.2 segment. But in addition, these sequence  com- 
parisons reveal a marked dominance (12/15) of AspSer in the 
first  two amino acid positions associated with multiple Jfl 
elements, and few or no N  region nucleotide additions in 
the CDR3 region. Receptor utilization in lymph nodes taken 
directly from MBP-immunized rats showed a similar pattern 
not seen in adjuvant-immunized control animals. CDR3 se- 
quences of Vf18.2 + control populations activated with Con 
A or derived from CFA-immune donors showed no such utili- 
zation of AspSer sequences and many more N region nucleo- 
tide additions. 
Materials and Methods 
Animals.  8-12-wk-old  female  Lewis  (LEW) rats were purchased 
from Harlan Sprague Dawley Inc. (Indianapolis, IN). 
Isolation of T Cell Clones.  The origins of all T cell clones used 
in this study have been previously described (13, 14). Briefly,  cells 
were obtained from the draining lymph nodes of animals under- 
going active EAE as a consequence of immunization 2 wk earlier 
1  Abbreviations used in this paper: EAE, allergic encephalomyelitis;  LEW, 
Lewis rats; MBP, myelin  basic protein; TdT, terminal deoxytransferase. 
with 50/~g of guinea pig MBP emulsified  in CFA containing 400 
I~g MFobacterium tuberculosis  strain H37Ra (Difco  Laboratories,  Inc., 
Detroit, MI). Lymphocyte suspensions were cultured briefly with 
antigen and T cell clones were derived in soft agar (13). Lympho- 
cytes were also obtained from the primary draining lymph nodes 
of animals immediately after recovery from active disease and T 
cell clones were established by limiting dilution (14). All clones 
derived from animals undergoing active disease, and two of the 
three clones from recovered  animals  assessed in this study have  been 
shown previously to be encephalitogenic in adoptive transfer ex- 
periments (13, 14). 
Isolation ofT CellHybridomas.  T cell  hybridomas  were produced 
by fusion of lymphoblasts from MBP-specific T cell lines to the 
murine TCR c~/fl- BWl100.129.237 cell line (15). Wells positive 
for cell growth in HAT medium were tested for I1.,2 production 
(10Vwell) after stimulation with MBP (20/~g/ml) in the presence 
of irradiated LEW spleen cells (5  x  10S/well)  and then subcloned 
at limiting dilution. All hybrids used in this study secreted Ib2 
when stimulated with whole MBP or with the synthetic peptide 
MBP68-88. 
Isolation of CD8- Con A  Blasts.  Vf18.2  + MBP 68-88-reactive 
T cells are almost exclusively  CD4+;  thus, for control purposes 
it was necessary  to prepare a population of  Con A-activated T cells 
enriched in CD4 from which a Vf18.2 cDNA library  could  be gener- 
ated and sequenced. A panning method (16) was used to deplete 
lymph node cells of the CD8 + subpopulation. Cells (2-3  x  107) 
were incubated on ice for 1 h in saturating amounts of superna- 
tants of post-log phase growth cultures of the OX8 hybridoma 
(anti-rat CD8) (17). The ceils were washed three times in HBSS 
(Fisher Scientific  Co. Allied Corp., Pittsburgh, PA), resuspended 
in 3 ml HBSS  containing 2% FCS 0.R. Scientific,  Woodland, CA), 
and then placed on petri dishes which had been coated overnight 
at 4~  with 10 ml goat anti-mouse Ig (10 ~g/ml; Fisher Scientific 
Co. Allied Corp.). Dishes were returned to 4~  for 1 h and nonad- 
herent cells were removed  by gentle pipetting. These nonadherent 
cells were panned a second time on anti-Ig coated dishes. Nonad- 
herent  ceils recovered with this protocol contained <5%  con- 
taminating cells of the CD8 + subset. Recovered cells were cul- 
tured at 2  x  10S/ml in RPMI 1640 containing 10% FCS, 5  x 
10 -s  M  2-ME,  2  mM glutamine,  100  /~g/ml penicillin/strep- 
tomycin,  and 5/~g/ml Con A. T cell  blasts were harvested  after  48 h. 
Determination of TCR Vfl Utilization.  TCR Vfl utilization was 
determined by PCR amplification  ofcDNA as described  previously 
(18). RNA was isolated from various cell populations after lysis 
in guanidinium isothiocyanate and phenol extraction (19) or cen- 
trifugation through a cesium chloride cushion (20). cDNA was 
prepared from 5-10 #g total RNA in Taq polymerase  buffer (50 mM 
KC1, 10 mM Trls-HC1 pH8.3,  2.5 mM MgCI2, 0.01% gelatin) 
in a 50/~1 reaction  volume  containing  40 mM 2-ME, 0.5 mM dNTPs 
(Pharmacia Fine Chemicals, piscataway, NJ), 20 U RNA guard 
(Pharmacia Fine Chemicals), 15 U AMV reverse  transcriptase (Phar- 
macia Fine Chemicals), and 1 /~M Cfl-specific oligonucleotide 
primer. This primer, 5'CATAGAAtTcCACTIGGCAGCGGAAGT- 
GGT3' (Genosys,  The Woodlands, TX), anneals to both rat TCR 
Cfll and Cfl2 mRNA. Bases in small letters denote changes in 
the TCR Cfl sequence made to create an EcoRI restriction en- 
donuclease site. The cDNA was then amplified  in 1.5 mM MgC12 
Taq buffer in the presence of 1/~M Cfl oligonucleotide, 1/~M of 
a 5' consensus  Vfl8 oligonucleotide  primer (Vf18-5'), 5'GGGCCGC- 
GGAACACATGGAAGCTGCAGTCAC3'  (containing a 5'-SaclI 
restriction endonuclease  site), 200/~M each dNTP (Pharmacia  Fine 
Chemicals), and 2 U Taq DNA polymerase  (Pharmacia  Fine Chem- 
icals). Samples were overlaid with mineral oil, heated for 5 min 
1468  CDR3  Sequences of Vf18.2 T Ceils in Experimental  Allergic Encephalomyelitis at 940C to denature DNA/RNA duplexes, and then subjected to 
30 amplification cycles of I  min at 94~  1.5 min at 550C,  and 
2 min at 72~  in a thermal cycler (Perkin-Elmer Corp., Norwalk, 
CT). After amplification, the samples were extracted with chloro- 
form to remove mineral oil, precipitated with ethanol, and digested 
with SaclI plus EcoRI (New England Biolabs, Beverly, MA). The 
resulting DNA was separated on a 1.4% agarose gel. The appro- 
priate size product was isolated using Prep-A-Gene (Bio-Rad Labora- 
tories, Richmond, CA) and ligated into the ScalI/EcoRI site of 
pBluescript II (Stratagene Inc., La Jolla, CA).  The ligation mix- 
ture  was  transformed  into  the bacterial  strain  DH5.  Multiple 
ampicillin-resistant colonies were selected and miniprep DNA was 
prepared by standard methods (21). The plasmid DNA was then 
sequenced directly by the dideoxy chain termination  method (22) 
using the Sequenase sequencing method (U.S. Biochemical, Cleve- 
land,  OH). 
Results 
V~ Utilization in EAE T Cells.  cDNA samples from 15 
different MBP 68-88-reactive T cell clones and hybridomas 
derived from MBP/CFA immunized LEW rats were ampl/fied 
using a V~8 consensus primer (V~8-5').  Sequence analyses 
of the PCR products indicated that all of the MBP-reactive 
T  cells used the VB8.2 gene segment. 
CDR3 Sequences in EAE T Cells.  Table 1 summarizes the 
details  of our  comparison  of CDR3  sequences  of LEW 
V/38.2 + TCR T  cell clones and hybridomas (Table 2), along 
with  several  independent  Vfl8.2 +  PCR  isolates  from 
MBP/CFA-immune lymph nodes (Table 3), with the CDR3 
sequences from  LEW  V138.2 +  TCR from  CD8-  Con  A 
blasts (Table 4) and CFA-immunized lymph nodes (Table 5). 
CD8-  blasts were used as control material because V~8.2 + 
T  cells reactive to MBP 68-88 are exclusively CD4 + . The 
clones and hybridomas were derived from rats immunized 
with intact MBP, and all were shown to be reactive in cub 
ture to the encephalitogenic peptide MBP 68-88. Lymph node 
isolates were derived from MBP-irnmunized animals, but their 
reactivity with  respect to MBP 68-88 is not known. 
There are two main findings with respect to this compari- 
son. First, of isolates from 15 different MBP peptide-reactive 
T cell clones and hybridomas, most (12) use AspSer and some 
(2) use ThrSer in the (N)D(N) region of CDR3.  Also, of 
25  different  MBP-immune  lymph  node  isolates,  nine  use 
AspSer. These numbers are markedly different for V/38.2 + 
TCR derived from Con  A  blasts  or CFA-immune  lymph 
nodes.  As reported by Burns et al.  (12)  and Chluba et al. 
(23), we define the COOH terminus of the V/38.2 segment 
as ending  at  amino  acids 91-94  (CysAlaSerSer). 
The second finding of interest in this comparison of V/38.2- 
associated CDR3 sequences concerns the number of N  re- 
gion nudeotide additions in CDR3. Fig.  1 shows a marked 
difference between TCK reactive to MBP 68-88 and TCK 
from control cells. A majority of the former (8/15) use only 
one nucleotide addition,  and in the latter,  most (25/31) of 
the V/38.2 + TCR use four to nine nucleotide additions. 
Utilization of different J/3 dements proved to be ordy some- 
what limited among the MBP 68-88-reactive T  cell clones 
and hybridomas (Table 1). There appears to be a dispropor- 
tionate usage ofJ/32.7.  The remaining  use J131.1, 1.3,  1.4, 
and 2.5. In comparison, JB utilization among control popu- 
lations of VB8.2 + Con A blasts and CFA immune lymph 
nodes is more extensive,  although  here too, JB2.7 appears 
to be used disproportionately  with V/38.2. 
Post EAE T Cells.  Finally,  we sequenced the TCR from 
three different MBP 68-88-reactive T cell clones derived from 
LEW rats that had recovered from paralytic EAE. These three 
clones  also  utilized  V/38.2 +,  but  only  one  of them  uses 
AspSer in CDR3 (Table 6). The two AspSer- clones, BB12 
and A2, were found to be encephalitogenic in adoptive transfer 
protocols (14). 
Table  1.  Summary of CDR3 Sequences of LEW V~8.2  TCR 
CDR3 sequences 
starting: 
PCR-amplified 
isolates  AspSer  ThrSer  Other  1.1  1.2 
JB utilization 
1.3  1.4  1.5  1.6  2.1  2.2  2.3  2.4  2.5  2.7 
MBP 68-88 rx 
Clones  and 
hybridomas 
MBP-immune 
lymph node 
Controls 
Con A blasts 
CFA-immune LN 
12/15  1/12 
9/25 
2/15 
1/15 
16/25 
15/15 
16/16 
1/16 
1/16 
3/12  2/12  1/12  5/12 
1/2  1/2 
1/1 
3/9  6/9 
2/16  1/16  3/16  3/16  6/16 
1/15  1/15  2/15  2/15  1/15  1/15  1/15  6/15 
2/16  2/16  2/16  2/16  1/16  1/16  5/16 
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 Table  3.  Junctional  Region Sequences of V~8.2 §  AspSer  + TCR from MBP-immune Lymph Nodes 
Isolate*  V  (N)D(N)  J 
91 
2*  V~8.2-CysA1  aSerSer  AspSerGly 
-tgtgccagcagt  ga  t  agtggg 
8  -CysA1  aSerSer  AspSerGly 
-tgtgccagcagt  gat  t  ccgga 
9*  -CysA1  aSerSer  AspSerGly 
--tgtgccagcagt  ga  t  agtggg 
1  -CysA1  aSerSer  AspSer 
--tgtgccagcagt  gacagc 
3  -CysAlaSerSer  AspSer 
-t  gtgccagcagt  gacagt 
4  -CysA1  aSerSer  AspSer 
-tgtgccagcagt  gacagc 
5  -CysAlaSerSer  AspSer 
-tgtgccagcagt  gacagc 
6  --CysAt  aSerSer  AspSer 
-tgtgccagcagt  gacagc 
7  --CysAlaSerSer  AspSerLeu 
--tgtgccagcagt  gacagtct  c 
AsnThrLeuPhe 
aacacct  tgt  tc 
AsnThrLeuPhe 
aacacct  tgt  tc 
AsnThrLeuPhe 
aacacct  tgt  t  c 
SerTyrGluGln 
t  cct  atgagcag 
SerTyrGluGln 
t  cct  atgagcag 
SerTyrGluGln 
t  cct  atgagcag 
SerTyrGluGln 
t  cct  atgagcag 
SerTyrGluGln 
t  cct  atgagcag 
SerTyrGluGln 
t  cct  atglugln 
J~2.4 
J~2.7 
* 25 vf18.2 isolates from lymph nodes of two MBP-immune rats were assessed; these nine contained AspSer. 
* These two isolates were derived from different animals. 
Discussion 
Several studies have focused attention on one interesting 
feature of EAE in experimental animal models: the limited 
usage of TCR Vc~ and V~ segments in immune responses 
to encephalitogenic fragments of myelin basic protein (7, 8, 
12, 23-25).  The T  cell response of B10.PL/J mice to MBP 
1-9 is dominated by VB2V~8.2 and Vo~4VB8.2 (7) but PL/J 
mice use Vc~4V~8.2 (8). SJL mice use VB4 and VB17 pre- 
dominantly in response to MBP 81-98 (24, 25). Despite the 
fact that it is a different species,  uses different MHC mole- 
cules for presenting antigen,  and responds to a different en- 
cephalitogenic fragment  (MBP 68-88),  the T  cell response 
of LEW rats in EAE,  like that  of B10.PL and PL/J mice, 
is also heavily dominated by Vc~2 and VBS.2 (12,  23, this 
report).  The implications  of this finding  are not clear. 
We report here that the CDR3 of V~8.2 + MBP-immune 
T  cells is also highly conserved in LEW rats with respect 
to some elements and shows somewhat limited usage with 
respect to others. Of 15 different PCR isolates from VB8.2 § 
T  cell clones and hybridomas,  all with demonstrable reac- 
tivity to MBP 68-88,  12 use AspSer in the first two amino 
acid positions of CDR3 and two others use ThrSer  (Table 
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2). Many (5/15) of these use Jf12.7 (Table 2) and a majority 
(8/15) use only a single N nucleotide addition (Fig. 1). This 
contrasts with Vf18.2 + control T  cells from Con A  blasts 
(Table 4) and CFA-immune lymph nodes (Table 5), where 
none of 31 CDR3 sequences use AspSer or ThrSer. Jfl utili- 
zation is more extensive in this control material,  although 
here too, Jf12.7 seems to have a disproportionate association 
(11/31) with VflS.2.  N  region  nucleotide addition  among 
control VBS.2 + T  cells is also more extensive, only 1 of 31 
with a single nucleotide addition and the majority showing 
four to nine N region additions (Fig.  1). Dominant presence 
of AspSer in the CDR3 region is also seen in material from 
MBP-immune lymph nodes. Here, 9/25 VB8.2 § isolates use 
AspSer, but none of 16 Vf18.2 + isolates from CFA-immune 
nodes use AspSer (Table 5, Fig.  1). It should be noted that 
three previously reported CDR3 sequences associated with 
VflS.2 in EAE were AspSer + (12,  23). 
It may be important  to point out in these considerations 
that even the limited number of N region additions we have 
indicated for MBP 68-88-reactive T  cells (Fig.  1) for two 
reasons may be an overestimate.  First, in the absence of known Table  4.  CDR3 Sequences of V~8.2 +  TCR from CD8-  LEW Con A  Lymphoblasts 
Isolate 
number  V  (N)  D(N)  J 
91 
1  V~8.2-Cy  sA1  a  S  e  r  Ar  gAr  gG1  yThrGl  uGl  nAl  a  Ty  rAs  pTy  rTh  r 
-tgtgccagcag  gagagggacaggggaggcc  t  a  tgact  acacc 
2  -CysAlaSerSer  PheGlnGluTrp  GlnAla 
-tgtgccagc  agt  t  t  t  caggagt  gg  caggcc 
3  -CysAaSerSer  GluGlyAsn  AlaGlu 
--tgtgccagcagt  gaggggaat  gc  tgaa 
4  -CysAl  aSerSer  GlyThrGly  AI  aGlu 
-tgtgccagcagt  ggcacgggg  gc  tgaa 
5  -Cy  sA1  a  S  e  r  Ar  gAs  pAr  gAr  g  As  nTh  rG1  yGl  u 
-tgtgccagcag  agacaggaga  aacaccgggcag 
6  -CysAlaSerSer  AlaGlnGlyAla  AsnThrGlyGlu 
-tgtgccagcagt  gcccagggggca  aacaccgggcag 
7  -CysA1  aSerSer  GluAsn  ThrAspLys 
--tgtgccagcagt  gagaa  t  acagacaag 
8  -Cy  sAl  a  S  e  r  S  e  r  As  pVa  1Me  tG1  yAs  p  Th  r  Leu 
-t  gtgccagc  agt  ga  t  gt  ga  t  gggt  gac  acc  t  tg 
9  -Cy  sAl  a  S  e  r  Tr  pGl  yAr  g  As  nG1  nGl  uTh  r 
-tgtgccagc  tggggacgg  aaccaagagacc 
10  -Cy  sA1  a  S  e  r  S  e  r  S  e  rMe  tAs  pLeuMe  t  G1  uG1  n 
-t  gt  gccagcagt  agt  a  t  gga  t  c  t  t  a  tg  gagcag 
11  -Cy  sA1  a  S  e  r  S  e  r  As  pG1  yG1  yG1  y  G1  uG1  n 
-tgtgccagcagt  gacggtggggga  gagcag 
12  -Cy  sAl  a  S  e  r  Th  r  P  r  oTh  rG1  yA1  a  G1  uGl  n 
-tgtgccagc  ag  accgac  tggggc  t  gagcag 
13  -Cy  sAl  a  S  e  r  S  e  r  A1  aGl  yP  r  o  Ty  rGl  uGl  n 
-tgtgccagcagt  gcgggt  ccc  t  a  tgagcag 
14  -Cy  sA1  a  S  e  r  S  e  r  Gl  uA1  aAs  pTr  pGl  yG1  y  Ty  rGluGl  n 
-t  gt  gccagcagt  gaggc  t  gac  tgggggggc  t  a  t  gagcag 
15  -Cy  sA1  a  S  e  r  Ar  gP  r  oG1  yTh  r  P  r  o  Ty  rGl  uG1  n 
-t  gt  gccagcag  acccgggac  t  ccc  t  a  tgagcag 
JB1.2 
J/~1.5 
JB2.1 
JB2.2 
JB2.3 
J/~2.4 
J/32.5 
J~2.7 
germline sequences for rat VB8.2 and the J3 elements, we 
cannot definitively determine the contribution  of P nucleo- 
tides (26) in our analysis. Second, while we have provision- 
ally assigned a 91-94 (CysAlaSerSer) as the COOH terminus 
of V~8.2 based on two previous studies of V~ utilization 
in the rat EAE model (12, 23),  and on the sequence data of 
VB8.2 usage in various cell populations in this paper, it must 
be recalled that the three murine V38 sequences terminate 
with CysAlaSerSerAsp (V/38.1 and 8.3) or CysAlaSerGlyAsp 
(VB8.2)  (27).  Thus,  the possibility exists that the Asp res- 
idue we have assigned to the D region is, in fact, the COOH 
terminus of rat VB8.2. Were this to be the case, the receptor 
sequences indicated for the CDR3 of two MBP 68-88-reactive 
clones (nos. 4 and 12) and one hybridoma (SIBIB10) (Table 
2) would be devoid of a D  region,  the result of a direct V 
to J recombination event. This would not violate the one- 
turn to two-turn joining rule (28). 
While lack of N region addition in TCKs has been reported 
previously in the fetal development of 3'/~-bearing T cells, 
the significance of this is not known. Since N  region addi- 
tion correlates with the existence of terminal deoxytransferase 
(TdT) activity (30), it is possible that ot/~expressing T cells 
developing before expression of high levels of TdT in the 
thymus may show no or only limited  N  region  additions. 
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 Figure 1.  Comparison  of the numbers  of  N region additions  in the CDR3 
of V/~8.2  +/3 chains of PCR isolates of MBP 68-88-reactive  T cell clones 
and hybridomas, and with the numbers of N region additions in VB8.2  + 
TCR from Con A lymphoblasts and CFA-immune LEW lymph nodes. 
ample of D  region expression without N  region addition in 
the control population  of Con A blasts and CFA-immune 
lymph  nodes  (Tables  4  and  5). 
Conserved/3 chain junctional region sequences have also 
been described previously in murine T  cell responses to an- 
tigen, but each of these studies indicates an interesting differ- 
ence with the rat model described here, where Vf18.2 chains 
use AspSer in the first positions of CDR3, a minimal number 
of N  region  additions,  and  extensive representation  of JB 
elements. 
(a)  In  the  B10.PL  mouse,  EAE  model Vf18.2 +  T  cells 
reactive to the encephalitogenic sequence MBP 1-9 express 
distinct  amino  acid sequences in the fl chain junctional re- 
gion (7, 8), but these conserved DB regions  are always as- 
sociated with  a particular J~  element,  whereas in  the rat, 
AspSer sequences are common to the CDR3 region of the 
fl chain  regardless  of the J/~ element  used. 
(b)  The  response  of I-Ed-restricted  T  cell clones  to  the 
110-121  fragment  of sperm whale myoglobin is highly ho- 
mogeneous, being dominated by V/38.2 + T  cells  (10),  but 
here the whole fl chain CDR3 junctional region, consisting 
of D~2.1  and J~2.6,  is also conserved. 
(c) In B10.A mice, specificity for cytochrome c requires ei- 
ther Asn or Asp in the first position of CDR3/~. In this case 
this amino acid is associated with two different J/~ elements 
and a considerable degree of diversity in the (N)D/~(N) re- 
gion  (6).  Similar  findings have been reported  for TCR re- 
sponses to  ~, repressor  protein  (9). 
A  second interesting  feature of EAE,  particularly  in the 
LEW rat,  is that  this is usually a monophasic,  self-limiting 
autoimmune  disease.  Rats become paralyzed  12-16 d  after 
immunization  with MBP, and then recover.  Recovered rats 
are refractory to subsequent attempts to induce active EAE, 
and this resistance appears to be mediated by regulatory T 
cells with antireceptor specificity  for V~8.2 + disease-causing 
T  cells.  Whether  recovery from paralytic EAE  and  subse- 
quent resistance  to further  disease induction  is a reflection 
of limited TCR utilization in MBP responses is not yet clear, 
but it is a critical issue in considerations of immunotherapeutic 
approaches  to at  least  some forms of autoimmune  disease. 
Considerable support exists for an antireceptor regulatory 
T  cell population  in recovery from  and induced  resistance 
to EAE in LEW rats.  First, V~8.2 + disease-causing T  cells 
reactive to MBP 68-88 can be used in  attenuated  form or 
in subclinical numbers as vaccines to induce resistance (31); 
T  cells from recovered animals can transfer resistance to sec- 
ondary recipients (32); and T cells from resistant animals have 
been shown to have lytic specificity for disease-causing T cell 
populations  (33).  In this respect the EAE resistance model 
in rats resembles closely a model of specifically induced resis- 
tance to GVH in F1 rats  after immunization  with  disease- 
causing T  cells of parental strain origin (34). Second, TCR 
peptides encompassing part of the CDR2 region of V/38.2 
are effective vaccines for inducing resistance  to EAE (35), and 
they are also therapeutically effective in reducing the severity 
of ongoing disease (36). This demonstrates that an immune 
response directed to a particular portion of TCR molecules 
highly conserved in a particular disease-causing T cell popu- 
lation can inhibit the function of cells bearing these receptors. 
If regulatory  T  cells  with  antireceptor  specificity are  a 
significant factor in recovery and resistance to autoimmune 
disease in the EAE model, an important question to be con- 
sidered concerns the identity of the idiotypic target  struc- 
ture.  Logic dictates that  this target  structure be conserved, 
as it is common to most if not all of the disease-causing T 
cells.  Some portion  of the VBS.2 sequence,  and,  from the 
Table  6.  Junctional Region Sequences of Vf18.2  + TCR from  LEW Rats after Recovery from EAE 
Clone  V  (N)  D(N)  J 
91 
BB12  VB8.2--CysA1  aSerSer 
--t  gt  gcc  agc  agt 
A2  -CysA1  aSer 
-t  gtgccagc 
E  --CysA1  aSerSer 
--t  gt  gccagcagt 
GlyThrGly 
gggacaggg 
ArgArgGlyGlyGlySer 
aggagagggggggggt  ca 
AspSer 
gacagc 
ThrAspLys  J~2.3 
acagataag 
GluThr  J~2.5 
gagaccc 
SerTyrGluGln  JB2.7 
tcctatgagcag 
1474  CDR3 Sequences of VB8.2 T Cells in Experimental Allergic Encephalomyelitis findings in this paper,  a portion  of the CDK3 expressing 
AspSer sequences,  are obvious candidates.  In this context, 
it is of interest that T cells reactive to MBP 68-88 are difficult 
to find in recovered animals  (14),  and AspSer sequences in 
the CDK3, which almost completely dominate Vf18.2 T cells 
present during active disease (12/15; Table 1), appear in only 
one of three VB8.2-positive, MBP 68-88-reactive T cell clones 
obtained from animals that have recovered from EAE (Table 
5). This finding is consistent with the possibility that recovery 
from disease depends upon immune elimination or inactiva- 
tion of Vf18.2 + AspSer + T  cells.  It is also of interest  that 
of the two clones from recovered animals lacking AspSer in 
CDK3, one of these (BB12) contained a CDR3 region de- 
void of N  region nucleotide additions. 
Previous findings that a Vf18.2 CDR2 region peptide (35), 
as well as a CDR3 peptide (37), of TCR used in the MBP 
response are effective vaccines for EAE raise the possibility 
that a natural target idiotype may be encompassed in these 
TCR regions. However, definitive proof for this would re- 
quire the demonstration that T cells obtained from animals 
recovering from EAE are reactive to these TCK peptides and 
that these peptide-reactive T  cells confer disease protection 
in secondary recipients. Finally,  it should be noted that this 
issue may be more complex. Previously one of us (D. Sun) 
has noted that donotypic regulation of the encephalitogenic 
response may also exist (33). 
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